Mexican Scientist Makes History: Dr. Mario Acosta Mejía Wins RIKEN’s Health Impact Award for Metabiotics® Discovery

A Historic Achievement for Mexican Science
In October 2025, Dr. Mario Acosta Mejía, CEO of Metabiogenix, was honored with one of the highest distinctions in the scientific community, the RIKEN Health Impact Award. This prestigious recognition, awarded by RIKEN, Japan’s foremost scientific institute, celebrates his pioneering discovery of Metabiotics®, a breakthrough in metabolic health. With this accolade, Dr. Acosta became the first Mexican scientist to receive the RIKEN Health Impact Award, marking a historic milestone for Mexican science and a significant moment for the global scientific community.

The award ceremony took place during a high-profile congress in Tokyo, attended by over 200 top scientists. At this event, Dr. Acosta’s work was highlighted for its transformative potential in the treatment of metabolic diseases, particularly fatty liver disease, and other chronic conditions linked to metabolism. The recognition underscores the growing importance of microbiome science in addressing global health challenges.

Metabiotics®: A New Era in Metabolic Medicine
Metabiotics® is an innovative class of bioactive microbial metabolites that are revolutionizing the field of metabolic health. Unlike traditional probiotics, which introduce beneficial bacteria to the gut, Metabiotics® deliver specific metabolites that actively influence critical metabolic pathways. This includes improving energy production, fat metabolism, and overall metabolic balance. Through years of meticulous research at the Japanese Medical Institute (JMI) and powered by cutting-edge fermentation technologies, Metabiotics® has shown clinically proven benefits in improving liver health, insulin resistance, glycemic control, and lipid profiles.

The product has emerged as a clinically validated solution to enhance microbiota health and reduce inflammation, making it a promising therapeutic option for individuals struggling with chronic metabolic conditions.

A Global Collaboration: Bridging Mexico and Japan
The development of Metabiotics® is the result of a successful collaboration between Mexican and Japanese research teams. The discovery builds upon the combined expertise of Innovation Labo and the Japanese Medical Institute, who together developed a unique biogenic system known as BIOTRA® ( cold fusion bio-reactors). This system integrates powerful antioxidants, polyphenols, Lactobacillus strains essential for maintaining metabolic health and Akkermansia metabolites in a unique formula, obtained through AI with a patented platform called Gene Sonar.

Metabiotics® represents a synthesis of knowledge from both countries, merging microbiome science with advanced fermentation technology to create a therapeutic solution that is already reshaping the landscape of metabolic health.

These new products are now being commercialized by Sanfer, the leading pharmaceutical company in Mexico, benefiting thousands of physicians and patients across the country, and soon in the United States and Latin America.

Recognizing Dr. Acosta’s Global Impact
During the Gala Dinner at the event, Dr. Acosta delivered the closing keynote, an honor reserved for individuals whose work is considered a game-changer in their field. His speech underscored the transformative potential of Metabiotics® in treating metabolic disorders and emphasized its role as a first-line therapeutic option for fatty liver disease, one of the most prevalent chronic diseases worldwide.

This recognition is not just a personal achievement for Dr. Acosta; it also signifies the global impact of Metabiogenix’s work in advancing biotechnology. As one of the leading scientists in microbiome research, Dr. Acosta is helping to redefine the future of metabolic medicine and microbiome health, an area of growing importance for human health.

Left to right: Dr. Marvin Edeas, CEO and Founder of the International Microbiome Society (website), Dr. Mario Acosta Mejía, CEO of Metabiogenix, Hiroshi Ohno, RIKEN Center for Integrative Medical Sciences, Japan

New Recognition: Best Microbiome Scientist in Mexico of 2025
In addition to the RIKEN Health Impact Award, Dr. Mario Acosta Mejía was also recently named the Best Microbiome Scientist in Mexico for 2025 by Best of Best Reviews. This distinction highlights his continued excellence in the field of microbiome science and metabolic health. His pioneering development of Metabiotics® has made a significant impact on understanding the role of the human microbiome in treating metabolic conditions such as fatty liver disease and insulin resistance.

For more information, visit www.metabiogenix.com.

Media Contact:
Mario Acosta Mejía
CEO
Metabiogenix
Email: info@metabiogenix.com
Website